A Cell‐Free Platform Based on Nisin Biosynthesis for Discovering Novel Lanthipeptides and Guiding their Overproduction In Vivo

Citations Over TimeTop 10% of 2020 papers

Abstract

Lanthipeptides have extensive therapeutic and industrial applications. However, because many are bactericidal, traditional in vivo platforms are limited in their capacity to discover and mass produce novel lanthipeptides as bacterial organisms are often critical components in these systems. Herein, the development of a cell-free protein synthesis (CFPS) platform that enables rapid genome mining, screening, and guided overproduction of lanthipeptides in vivo is described. For proof-of-concept studies, a type I lanthipeptide, nisin, is selected. Four novel lanthipeptides with antibacterial activity are identified among all nisin analogs in the National Center for Biotechnology Information (NCBI) database in a single day. Further, the CFPS platform is coupled with a screening assay for anti-gram-negative bacteria growth, resulting in the identification of a potent nisin mutant, M5. The titers of nisin and the nisin analog are found to be improved with CFPS platform guidance. Owing to the similarities in biosynthesis, the CFPS platform is broadly applicable to other lanthipeptides, thereby providing a universal method for lanthipeptide discovery and overproduction.

Related Papers

• → Effective control of Listeria monocytogenes by combination of nisin formulated and slowly released into a broth system(2003)125 cited
• → Improved antimicrobial activity of nisin-incorporated polymer films by formulation change and addition of food grade chelator(2001)124 cited
• → Isolation and characterisation of two degradation products derived from the peptide antibiotic nisin(1989)104 cited
• → Activity and Export of Engineered Nisin-(1-22) Analogs(2011)15 cited
• → بررسی اثر ضد باکتریایی نایسین به دو فرم آزاد و نانوانکپسوله در لیپوزوم بر ماندگاری و کاهش جمعیت لیستریایی پنیر سفید ایرانی فراپالایش(2011)1 cited